This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Comparative Study of Oestradiol Suppression: Zoladex 10.8mg/3 Month vs. 3.6mg/Month in ER +ve EBC Pre-menopausal Patients

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: March 16, 2006
Last updated: December 20, 2009
Last verified: December 2009
The primary purpose of this study is to establish if a 10.8 mg dose of ZOLADEX given 3 monthly is non-inferior to a 3.6 mg dose of ZOLADEX given monthly in terms of oestradiol suppression in patients with oestrogen receptor positive early breast cancer.

Condition Intervention Phase
Breast Cancer Drug: Goserelin acetate Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Randomized, Parallel Group, Multicentre Study to Compare Oestradiol Suppression Between ZOLADEX 10.8 mg Depot Given 3 Monthly and ZOLADEX 3.6 mg Depot Given Monthly in Pre-menopausal Patients With ER Positive Early Breast Cancer

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Zoladex 10.8mg depot (every 12 weeks) is non-inferior to Zoladex 3.6mg depot (every 4 weeks) in terms of oestradiol (E2) suppression in patient population by assessment of area under the curve of E2 concentration during the first 24 weeks of treatment. [ Time Frame: every 12 weeks ]

Secondary Outcome Measures:
  • Zoladex 10.8mg has similar safety and tolerability profile to Zoladex 3.6mg. Examination of goserelin pharmacokinetics (PK) in Japanese patients after injection of Zoladex 10.8mg. Efficacy of Zoladex 10.8mg is similar to 3.6mg by assessment of DFS. [ Time Frame: every 12 weeks ]

Enrollment: 170
Study Start Date: February 2006
Study Completion Date: February 2009
Primary Completion Date: August 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Zoladex 3-month depot
Drug: Goserelin acetate
injection 10.8 mg every 3 months
Other Name: Zoladex
Experimental: 2
Zoladex 1-month depot
Drug: Goserelin acetate
Injection 3.6 mg monthly
Other Name: Zoladex


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Pre-menopausal women aged 20 years or over with histological/cytologically-confirmed ER +ve breast cancer who have undergone radical surgery and WHO performance status 0,1 or 2.

Exclusion Criteria:

  • Evidence of metastatic disease, previous bilateral oophorectomy or radiotherapy to the ovaries, previous chemotherapy, breast surgery completed over 12 weeks before starting trial treatment, previous neo-adjuvant/adjuvant hormonal breast cancer therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00303524

Research Site
Chiba, Japan
Research Site
Fukuoka, Japan
Research Site
Fukushima, Japan
Research Site
Isehara, Japan
Research Site
Kagoshima, Japan
Research Site
Kashiwa, Japan
Research Site
Kawasaki, Japan
Research Site
Kitakyushu, Japan
Research Site
Kumamoto, Japan
Research Site
Matsuyama, Japan
Research Site
Miyazaki, Japan
Research Site
Nagoya, Japan
Research Site
Niigata, Japan
Research Site
Osakasayama, Japan
Research Site
Osaka, Japan
Research Site
Ota, Japan
Research Site
Saitama, Japan
Research Site
Shimotsuke, Japan
Research Site
Suita, Japan
Research Site
Tokorozawa, Japan
Research Site
Tokyo, Japan
Research Site
Utsunomiya, Japan
Sponsors and Collaborators
Study Director: AstraZeneca Japan Medical Director, MD AstraZeneca
  More Information Identifier: NCT00303524     History of Changes
Other Study ID Numbers: D8664C00004
Zoladex EBC Study
Study First Received: March 16, 2006
Last Updated: December 20, 2009

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents processed this record on August 18, 2017